ArcticZymes Technologies is a new company record. Its research profile isn't ready yet.
arcticzymes.comCrawled Nov 9, 2026
ArcticZymes provides scalable enzyme supply solutions for diverse biotechnological needs.
The page offers solutions for removing residual DNA in diagnostics, metagenomics, and bioprocessing.
The page explores ArcticZymes’ enzyme applications in molecular research, diagnostics, and therapeutics, including viral bioprocessing and PCR carry-over prevention.
The page describes GMP-grade M-SAN HQ for efficient DNA removal at physiological salt concentrations as a Benzonase alternative.
The page presents a whitepaper on how different nucleases impact viral vector manufacturing yield, downstream processes, and product purity.
The page offers expert content on enzyme innovation and workflows for bioprocessing and molecular diagnostics.
The page shares metagenomics resources, including protocols, webinars, and clinical insights for pathogen detection and DNA removal.
The page offers a whitepaper analyzing how nuclease strategy affects viral vector yield, filtration, and cost per dose.
Tromsø, Norway, June 27th, 2024—ArcticZymes Technologies (OSE: AZT) Announces Announces New Chairman and Board Members
ArcticZymes Technologies ASA (OSE: AZT), in collaboration with the Austrian Centre of Industrial Biotechnology (acib), has extended their joint research partnership for another three years.
ArcticZymes announces a new European distributor agreement with Brenntag Specialists Pharma for the SAN-HQ and M-SAN HQ product lines.
ArcticZymes launches RiboClean dsDNase and RiboCleave 1, enzymes for RNA therapeutics manufacturing and analysis, coinciding with the 33rd ESGCT Annual Congress.
The page enables requests for enzyme supply quotes, including bulk orders and custom formulations.
The page introduces ArcticZymes’ leadership team and board, focusing on enzyme solutions for bioprocessing, molecular biology, and diagnostics.
Access corporate information for ArcticZymes Technologies, including governance, articles of association, share capital and company structure details.
Explore ArcticZymes' ESG approach, including environmental, social and governance commitments, sustainability initiatives and corporate responsibility.
The page highlights ArcticZymes’ technical support for enzyme applications.
The page offers expert guidance and support for bioprocessing and diagnostic workflows.
The page provides a Letter of Authorization (LOA) to support regulatory submissions using the SAN HQ GMP DMF.
The page offers the quality dossier for SAN HQ GMP to support regulatory submissions.
The company develops enzymes for biomanufacturing and diagnostics, including COD UNG and salt-active nucleases.
ArcticZymes’ Board of Directors outlines its corporate governance policy, adhering to NUES recommendations and the Norwegian Accounting Act.
Review ArcticZymes remuneration guidelines, outlining executive compensation policy, governance and alignment with long-term business strategy.
